Phillip Frost, the CEO and Chairman of OPKO Health, Inc. (NASDAQ:OPK), has increased his stake in the company by purchasing 500,000 shares of common stock. According to InvestingPro data, this aligns with broader management share purchases, while analysts maintain a Strong Buy rating with price targets ranging from $2.00 to $8.50. The shares were acquired at a weighted average price of $1.4817 per share, amounting to a total investment of approximately $740,850. The transactions occurred on January 15, 2025, and reflect Frost's indirect ownership through the Frost Gamma Investments Trust. Following this purchase, Frost now holds a total of 213,036,477 shares indirectly. InvestingPro analysis indicates the stock is currently fairly valued, with a Financial Health score of FAIR. Discover 8 more exclusive ProTips and comprehensive valuation metrics with InvestingPro's detailed research report.
In other recent news, Opko Health (NASDAQ:OPK) has been the subject of multiple significant developments. The company's Q3 2024 financial results showcased a net income of $24.9 million, a significant improvement from the previous year's net loss, despite a decrease in revenue. Additionally, Opko Health sold BioReference Health's clinical diagnostics assets for $237.5 million and reported growth in its 4K score test for prostate cancer and oncology testing volume.
Furthermore, H.C. Wainwright analyst Yi Chen reaffirmed a Buy rating on shares of Opko Health, following the commencement of Phase 1 trial for its Epstein-Barr virus (EBV) vaccine candidate, MDX2201, by its subsidiary, ModeX Therapeutics. The company's collaboration with Merck (NS:PROR) on this vaccine could lead to milestone payments of up to $872.5 million.
Opko Health also partnered with Pfizer (NYSE:PFE) on the launch of NGENLA, and repurchased 24 million shares under its share buyback program. Despite a decrease in Q3 revenue, the company projects future revenue for Q4 2024 to be between $155 million and $160 million, with operational profitability expected by the end of the year. These recent developments highlight Opko Health's strategic focus on profitability and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.